Phase I Trial of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
The primary objective is to determine recommended phase II doses for the combination
dacarbazine and bortezomib administered weekly.
Secondary objectives are to determine the maximum tolerated dose combination and to observe
anti-tumor activity in terms of response rate(s), duration of response, time to progression,
and time on treatment (a measure of both antitumor activity and treatment tolerance).
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Safety as measured by serious adverse events
Andrew Poklepovic, MD
Massey Cancer Center
United States: Institutional Review Board
|Dartmouth Hitchcock Medical Center||Lebanon, New Hampshire 03756|
|Massey Cancer Center/Virginia Commonwealth University||Richmond, Virginia 23298|